ACP2 and colorectal carcinoma: Surprisingly, stage II and III CRC patients with high expression of ACP2 showed significantly better seven-year survival in response to chemotherapy compared with those with low expression of ACP2 in stage II and III CRC (P = 0.002 versus p = 0.136; Figure 2C and 2D).